Our findings uncover the regulatory mechanism by which OVOL2 represses FAO in breast cancer and propose that targeting JAK/STAT3‐FAO is a potential strategy for OVOL2‐absent TNBC therapy. Here, STAT3 is linked to breast carcinoma.